常山药业(300255) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥741,039,767.24, an increase of 18.04% compared to the same period last year[3] - Net profit attributable to shareholders was ¥50,125,991.97, a decrease of 32.23% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥48,816,334.10, down 31.68% from the previous year[3] - Total operating revenue for the period reached ¥2,158,441,271.38, an increase from ¥1,637,611,319.05 in the previous period, representing a growth of approximately 31.8%[26] - Net profit for the period was ¥205,052,547.28, slightly up from ¥203,457,633.07, reflecting a growth of approximately 0.8%[29] - The net profit attributable to the parent company was approximately ¥207.09 million, compared to ¥204.62 million in the previous period, reflecting a slight increase[32] - The total comprehensive income attributable to the parent company was approximately ¥198.04 million, down from ¥212.17 million in the previous period[32] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,120,131,094.26, reflecting an increase of 11.98% from the end of the previous year[3] - The total assets of the company reached ¥5,120,131,094.26, compared to ¥4,572,556,783.14 in the previous period, an increase of approximately 12%[25] - Total liabilities increased to ¥2,070,893,213.91 from ¥1,719,328,775.53, representing a growth of about 20.4%[25] - The company's equity attributable to shareholders rose to ¥3,045,623,851.87 from ¥2,847,580,472.06, indicating an increase of approximately 6.9%[25] Cash Flow - The company's cash flow from operating activities showed a net inflow of ¥-142,157,545.23, a significant improvement of 64.70% year-on-year[3] - Cash inflows from operating activities totaled approximately ¥2.41 billion, up from ¥1.69 billion in the previous period, indicating strong revenue growth[36] - Cash outflows from operating activities increased to approximately ¥2.55 billion from ¥2.09 billion, resulting in a net cash flow from operating activities of approximately -¥142.16 million, an improvement from -¥402.68 million in the previous period[36] - Cash and cash equivalents increased by 126.13% year-on-year, attributed to improved cash flow from operating activities[10] - The cash and cash equivalents at the end of the period amounted to approximately ¥517.52 million, down from ¥578.98 million at the end of the previous period[39] Shareholder Information - Total number of common shareholders at the end of the reporting period was 35,745[12] - The largest shareholder, Guotou High-tech Investment Co., Ltd., holds 35.69% of shares, totaling 333,644,728 shares[12] - The company plans to unlock 25% of the shares held by executives annually during their tenure[16] - The company repurchased 15,906,000 shares in 2020, representing 1.70% of total shares[15] - The total number of restricted shares at the beginning of the period was 250,233,546, remaining unchanged[16] Operational Metrics - The company experienced an 80.78% increase in operating costs, primarily due to higher sales volumes and rising raw material prices[7] - Total operating costs amounted to ¥1,933,766,897.05, up from ¥1,405,472,840.96, indicating a rise of about 37.4%[26] - Gross profit for the period was ¥224,674,374.33, compared to ¥232,138,478.09 in the previous period, showing a slight decrease of around 3.2%[29] - Research and development expenses increased to ¥106,404,718.54 from ¥84,614,578.27, marking a rise of about 25.7%[29] Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance revenue growth[28] - The company has not disclosed any significant new strategies or product developments in the current report[18]